Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2004

View Archived Issues

Aplidin enters phase II for hematological malignancies

Combunox approved for short-term management of acute moderate/severe pain

Extended indication for Fludara oral in Europe

Submission of Aryplase BLA

Early atherosclerotic coronary calcification may be pathogen-induced

ZD-0473 effective in chemotherapeutic-resistant human colorectal cancer cell lines

Treatment with recombinant diabody and thalidomide promising in preclinical model of lymphoma

New interferon shows potent antiviral and proliferative efficacy

Putative melatonin receptor agonist promising for treatment of glaucoma

Preliminary data on the immunogenicity of ChimeriVax-Dengue vaccine

AVI-4126 reported to improve outcome in patients undergoing PCI

Edaravone shows promise in the reduction of infarct size after AMI

Clinical evidence for the antihypertensive effects of rosiglitazone in type 2 diabetes

MultiHance receives FDA approval

Atacand approved in Europe for treatment of chronic heart failure

Orathecin NDA action date delayed by new data

Reliant to market newly approved Omacor in U.S.

Four patents covering new treatments of cancer

Novartis temporarily withdraws European application for Prexige

New formulations of tegaserod claimed by Novartis

Novartis researchers prepare parenteral formulations of mycophenolic acid

Kissei describes SGLT inhibitors in patent literature

Takeda scientists prepare MCH receptor antagonists for obesity, depression, and anxiety

Antiinflammatory agents in early development at Minophagen for pain, arthritis, etc.

Agents for the treatment of arthritis claimed by Sumitomo

Sankyo researchers prepare and test PTP inhibitors

FDA approves new indication for Nexium

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.